![Wasp on a wooden platform [Credit: University of Pennsylvania].](https://www.drugtargetreview.com/wp-content/uploads/Vespula-lewisii-wasp-750x500.jpg)
![Wasp on a wooden platform [Credit: University of Pennsylvania].](https://www.drugtargetreview.com/wp-content/uploads/Vespula-lewisii-wasp-e1602594547599.jpg)
news
Novel antimicrobial molecules derived from wasp venom
Altering the mastoparan-L (mast-L) peptide found in Vespula lewisii wasp venom, researchers created several novel antimicrobial molecules.
List view / Grid view
Antimicrobials
![Syringe drawing liquid from a vial labelled 'REMDESIVIR', on a background of abstract SARS-CoV-2 particles [Credit: ffikretow@hotmail.com / Shutterstock.com].](https://www.drugtargetreview.com/wp-content/uploads/remdesivir-SARS-CoV-2-750x500.jpg)
![Syringe drawing liquid from a vial labelled 'REMDESIVIR', on a background of abstract SARS-CoV-2 particles [Credit: ffikretow@hotmail.com / Shutterstock.com].](https://www.drugtargetreview.com/wp-content/uploads/remdesivir-SARS-CoV-2-scaled-e1602154798857.jpg)
news
Researchers identify a potential remdesivir resistance mechanism in SARS-CoV-2
Exploring how the Ebola virus develops remdesivir resistance has highlighted a mutation that could allow SARS-CoV-2 to do the same.
news
Platform for hit-to-lead identification of antibacterial lysins developed
A group of scientists has created a novel high-throughput hit-to-lead development platform to identify engineered antibacterial lysins.
whitepaper
Webinar: Optimised workflow for rapid identification of neutralising antibodies against viral particles
Helping in the race to identify effective neutralising antibodies against the spike protein of SARS-CoV-2 virus as the COVID-19 global death rate continues to rise.
news
Two compounds exhibit antibacterial properties against tuberculosis
Tested on two assays, researchers have shown that Redx03863 and Redx04739 can combat tuberculosis and do not lead to resistance.
news
Beautyberry leaf could be the secret to combatting MRSA infections
A compound extracted from the leaf of the American beautyberry re-sensitised methicillin-resistant Staphylococcus aureus (MRSA) to beta-lactam antibiotics.
news
Approach to produce antibiotic compounds from actinobacteria developed
Researchers have created a method to promote the production of new antibiotic or antiparasitic compounds from the genomes of actinobacteria.
webinar
Drug repurposing approaches to fast track development of new therapies for COVID-19
26 June 2020 | By Tecan
This webinar described the recent efforts to identify small molecule therapeutics for the treatment of SARS-CoV-2 infection and COVID-19 disease.
whitepaper
Application note: High-throughput pathogen detection using a novel MagMAX kit and OpenArray technology
Automated detection and isolation of pathogens for multiple samples types.
whitepaper
ebook: High-content analysis and infectious disease
Learn how you could use high-content analysis for functional & phenotypic assays in your infectious disease research or drug discovery.
article
Begin with the end in mind: designing synthetic antibiotics with a universal mechanism of action
James Graham from Recce Pharmaceuticals discusses how a new class of synthetic antibiotics could be the key to preventing the spread of antibiotic resistance.
news
Novel antibiotic peptide fights ‘superbug’ lung infections in mice
Scientists have developed a new antimicrobial peptide therapy named D8 with high efficacy and low toxicity in mice which could be used to fight lung infections.
news
Glycomimetics could prevent COVID-19 from infecting human cells
Glycomimetics, a novel class of antivirals, prevented influenza, herpes viruses and papillomaviruses from infecting cells in animal models and could show similar efficacy against COVID-19.
article
How are seasonal influenza vaccines developing?
With the global ageing population at risk of death from influenza, what is pharma doing to develop more effective vaccines to combat the virus?
news
Blocking bacterial competence could prevent antibiotic resistance
Scientists suggest competence-blocking, ‘anti-evolution’ drugs could be administered alongside antibiotics to prolong the period before bacterial resistance emerges.
